Binge Eating Disorder Market by Treatment Type (Digital Therapeutics, Pharmacotherapy, Psychotherapy), Treatment Setting (Inpatient, Outpatient), Distribution Channel, End User - Global Forecast 2025-2032
Description
The Binge Eating Disorder Market was valued at USD 587.86 million in 2024 and is projected to grow to USD 623.43 million in 2025, with a CAGR of 6.20%, reaching USD 951.58 million by 2032.
An authoritative introduction defining the clinical, technological, and policy context that frames modern approaches to binge eating disorder care and stakeholder priorities
Binge eating disorder has emerged as a critical focus for clinicians, payers, digital innovators, and policy leaders due to rising clinical recognition and shifting care paradigms. This executive summary provides a structured entry point that synthesizes clinical drivers, therapeutic modalities, delivery innovations, and commercial pressures shaping how stakeholders assess unmet needs, patient journeys, and investment priorities. The introduction situates the disorder within the broader mental health and metabolic comorbidity context, clarifies recent advances in diagnostic clarity, and outlines the evolving role of technology-enabled care in enhancing access and adherence.
Stakeholders are adapting to a landscape where evidence-based psychotherapy models coexist with pharmacologic research and an expanding digital therapeutics ecosystem. Alongside this, fragmentation in treatment access and variability in payer policies continue to influence clinical uptake and real-world outcomes. This section frames the remainder of the report by articulating core assumptions, defining key terms used throughout, and setting expectations for the types of evidence synthesized, including clinical trial data, regulatory developments, and real-world implementation trends. By aligning shared terminology and contextualizing recent momentum, the introduction prepares readers to interpret deeper analyses and to prioritize actions informed by both clinical impact and operational feasibility.
A concise synthesis of the pivotal shifts reshaping care delivery, financing, and therapeutic innovation across the binge eating disorder ecosystem
The treatment landscape for binge eating disorder has undergone several transformative shifts that are redefining care pathways and competitive dynamics. First, there is an increasing integration of digital therapeutics alongside traditional psychotherapy and pharmacotherapy, driven by improved mobile engagement models and a push for scalable behavioral interventions. Second, regulatory and reimbursement frameworks are slowly adapting to recognize the role of technology-enabled care, which in turn incentivizes investment in validated digital platforms and hybrid delivery models.
Third, precision in therapeutic targeting is improving as clinical research differentiates subgroups by comorbidity profiles and behavioral phenotypes, prompting more nuanced treatment algorithms that blend cognitive interventions with pharmacologic agents when indicated. Fourth, stakeholder collaboration is intensifying, with providers, payers, and technology developers exploring value-based agreements and outcome-based pilots to demonstrate cost-effectiveness and long-term benefit. Together, these shifts are creating an environment where multidisciplinary care, supported by interoperable data flows and outcome measurement, becomes the expectation rather than the exception, and where new entrants can compete by delivering demonstrable improvements in access, adherence, and measurable clinical outcomes.
An analytical review of how the cumulative effects of United States tariff adjustments in 2025 influenced supply chains, procurement choices, and cost strategies relevant to treatment delivery
In 2025, changes to tariff and trade policy in the United States influenced supply chains and procurement costs across several healthcare segments that intersect with binge eating disorder management. Supply chain sensitivity affected the availability and pricing of certain imported components used in digital devices and software-enabled services, while pharmaceuticals and medical devices experienced input-cost variability that cascaded into distribution and contracting negotiations. These pressures prompted some providers and specialty centers to reassess sourcing strategies, prioritize domestic procurement where feasible, and seek long-term supplier agreements to mitigate volatility.
Conversely, tariff-related cost shifts accelerated interest in localized manufacturing for hardware-dependent digital therapeutic platforms and created opportunities for domestic software vendors to gain pricing competitiveness relative to imports. For health systems and payers, the cumulative impact has emphasized the importance of robust procurement playbooks, scenario planning for input cost fluctuation, and contract clauses that share risk across stakeholders. As a result, organizations increasingly favor flexible contracting models and outcome-based arrangements that can absorb short-term cost variability while protecting long-term patient access to evidence-based treatment options.
Actionable segmentation insights that map therapeutic modalities, delivery channels, patient cohorts, and care settings to practical clinical and commercial levers
A nuanced view of market segmentation illuminates clinically meaningful pathways and operational priorities across treatment type, distribution channel, end user, and treatment setting. Based on treatment type, the landscape is studied across Digital Therapeutics, Pharmacotherapy, and Psychotherapy, with Digital Therapeutics further categorized into Mobile App and Web Based modalities, Pharmacotherapy further divided into Antidepressants, Antiepileptics, and Stimulants, and Psychotherapy further classified into Cognitive Behavioral Therapy, Dialectical Behavior Therapy, and Interpersonal Psychotherapy. Each of these subsegments carries distinct evidence requirements, implementation barriers, and value propositions, whether the emphasis is on scalable behavioral coaching, targeted symptom reduction, or integrated comorbidity management.
Based on distribution channel, the pathways considered include Home Healthcare, Hospitals And Clinics, Online Platforms, and Specialty Treatment Centers, each offering different access dynamics, clinician involvement levels, and reimbursement considerations. Based on end user, the analysis distinguishes Adolescents, Adults, and Elderly populations, recognizing divergent clinical presentations, engagement patterns, and caregiver involvement that affect both product design and care protocols. Based on treatment setting, the market is examined across Inpatient and Outpatient contexts, noting that inpatient pathways demand acute stabilization and multi-disciplinary coordination while outpatient models prioritize continuity, stepped care approaches, and digital augmentation. By mapping these multidimensional segments together, the analysis reveals where clinical need, payer interest, and commercial opportunity most strongly converge.
Key regional perspectives highlighting how clinical adoption, reimbursement complexity, and digital readiness drive differentiated strategies across global markets
Regional dynamics shape investment priorities, regulatory approaches, and adoption trajectories for binge eating disorder interventions. In the Americas, clinical awareness and payer innovation create a receptive environment for scalable digital solutions and outcome-driven pilots in integrated delivery systems. The United States, in particular, exhibits a growing appetite for hybrid care models that marry evidence-based psychotherapy with pharmacologic adjuncts, while Latin American markets demonstrate emerging interest in digital care to bridge provider shortages and urban-rural access gaps.
Across Europe, Middle East & Africa, regulatory heterogeneity and diverse reimbursement architectures mean that adoption is uneven but growing in markets with centralized health technology assessment pathways that can recognize long-term benefits. Stakeholders in these regions increasingly focus on cross-border clinical evidence generation and regionally tailored engagement strategies. In the Asia-Pacific region, rapid digital penetration, a strong appetite for mobile-first health solutions, and large adolescent and young adult populations present significant opportunities for mobile-based interventions and culturally adapted psychotherapeutic content. However, variations in stigma, health literacy, and service delivery capacity require nuanced localization strategies to realize adoption at scale. Taken together, regional strategies must balance standardized evidence packages with localized implementation planning to achieve sustainable uptake.
Insights into the strategic behaviors and collaborative models of pharmaceutical, digital therapeutics, and provider organizations shaping competitive dynamics
Leading organizations influencing the binge eating disorder ecosystem span pharmaceutical innovators, digital therapeutics developers, specialty treatment centers, and integrated provider networks. Pharmaceutical firms continue to pursue rigorous clinical development programs that explore pharmacologic mechanisms addressing compulsive eating behaviors and comorbid mood disorders, with an emphasis on safety, tolerability, and real-world effectiveness. Digital therapeutics companies focus on validated behavioral programs, engagement science, and interoperability, positioning their solutions as scalable complements or alternatives to traditional psychotherapy.
Specialty treatment centers and hospital systems act as critical early adopters and validation partners, running pragmatic pilots and providing longitudinal outcome data that inform payer decisions. Startups and academic collaborations drive innovation in measurement-based care and passive digital phenotyping, while established clinical research institutions contribute expertise in trial design and long-term follow-up. Across all these actors, strategic collaborations and licensing arrangements are increasingly common as companies seek to combine pharmacologic approaches with digital platforms or integrate evidence-based psychotherapies into reimbursable care pathways. Competitive advantage is conferred by demonstrable clinical outcomes, payer-aligned value propositions, and scalable implementation frameworks that lower the barrier for widespread adoption.
Practical and prioritized recommendations for leaders to validate clinical impact, secure payer alignment, and scale integrated care models for binge eating disorder
Industry leaders can take concrete actions to accelerate adoption, demonstrate value, and improve patient outcomes. First, invest in rigorous, pragmatic evidence generation that pairs clinical endpoints with real-world adherence and health-economic analyses to speak directly to payer concerns. Second, design integrated care pathways that combine validated psychotherapy protocols, appropriate pharmacologic options, and technology-enabled support to improve continuity and measurable outcomes across outpatient and inpatient settings. Third, prioritize interoperability and data standards to enable outcome tracking, seamless referral workflows, and the ability to participate in value-based contracting.
Fourth, tailor market access strategies by patient cohort, recognizing the distinct needs of adolescents, adults, and elderly groups, and by distribution channel, aligning product features with home healthcare, hospital, online platform, or specialty center workflows. Fifth, mitigate supply chain risk through diversified sourcing, flexible contracting, and contingency planning in response to trade and tariff pressures. Finally, pursue partnerships with payers and integrated delivery networks to pilot outcome-based reimbursement models that align incentives around sustained clinical improvement rather than episodic service delivery. These recommendations, implemented in concert, will position organizations to translate clinical innovation into durable, scalable care models.
A clear description of the mixed-methods research design, evidence sources, and validation steps used to generate actionable conclusions while acknowledging methodological limitations
The research underpinning this executive summary employs a mixed-methods approach that synthesizes peer-reviewed clinical literature, regulatory announcements, qualitative interviews with clinicians and payer executives, and a structured review of implementation case studies. Evidence selection prioritized randomized controlled trials, high-quality cohort studies, and pragmatic implementation reports that report clinically relevant endpoints and adherence metrics. Supplementary insights derive from expert interviews conducted with multidisciplinary clinicians, behavioral health directors, digital health product leaders, and policy advisors to capture practical barriers and enablers in real-world settings.
Data synthesis used thematic analysis to identify recurring implementation challenges and opportunities, supplemented by cross-validation against regulatory trends and reimbursement policy updates. Where applicable, gap analysis highlights areas needing further evidence, including long-term outcomes and comparative effectiveness across combined modality approaches. Limitations of the methodology include variability in outcome measurement across studies and heterogeneity in intervention designs, which the report addresses by standardizing endpoint definitions and transparently documenting inclusion criteria. This methodological rigor supports actionable conclusions while acknowledging areas where additional primary research would strengthen decision confidence.
A concise conclusion tying together clinical advances, delivery model evolution, and strategic priorities to guide stakeholders toward scalable, patient-centered care
This executive summary synthesizes the key dynamics shaping binge eating disorder care, highlighting the interplay between therapeutic innovation, delivery models, and system-level incentives. Clinically, the field is moving toward integrated approaches that pair psychotherapy with judicious pharmacologic support and technology-enabled adherence tools. Operationally, distribution choices and treatment settings influence implementation complexity and require tailored engagement strategies. Strategically, payer alignment and demonstrable value are central to mainstreaming new modalities and enabling sustainable patient access.
Looking forward, stakeholders who prioritize pragmatic evidence generation, invest in interoperable systems for outcome measurement, and pursue collaborative reimbursement pilots will be best positioned to scale effective interventions. The conclusions stress the importance of balancing near-term feasibility with long-term outcome monitoring, and of adopting patient-centered design to ensure interventions are acceptable, accessible, and equitable. Ultimately, the path to broader impact lies in coordinated efforts across clinical research, technology development, and payer engagement to transform promising innovations into standard care pathways that measurably improve lives.
Note: PDF & Excel + Online Access - 1 Year
An authoritative introduction defining the clinical, technological, and policy context that frames modern approaches to binge eating disorder care and stakeholder priorities
Binge eating disorder has emerged as a critical focus for clinicians, payers, digital innovators, and policy leaders due to rising clinical recognition and shifting care paradigms. This executive summary provides a structured entry point that synthesizes clinical drivers, therapeutic modalities, delivery innovations, and commercial pressures shaping how stakeholders assess unmet needs, patient journeys, and investment priorities. The introduction situates the disorder within the broader mental health and metabolic comorbidity context, clarifies recent advances in diagnostic clarity, and outlines the evolving role of technology-enabled care in enhancing access and adherence.
Stakeholders are adapting to a landscape where evidence-based psychotherapy models coexist with pharmacologic research and an expanding digital therapeutics ecosystem. Alongside this, fragmentation in treatment access and variability in payer policies continue to influence clinical uptake and real-world outcomes. This section frames the remainder of the report by articulating core assumptions, defining key terms used throughout, and setting expectations for the types of evidence synthesized, including clinical trial data, regulatory developments, and real-world implementation trends. By aligning shared terminology and contextualizing recent momentum, the introduction prepares readers to interpret deeper analyses and to prioritize actions informed by both clinical impact and operational feasibility.
A concise synthesis of the pivotal shifts reshaping care delivery, financing, and therapeutic innovation across the binge eating disorder ecosystem
The treatment landscape for binge eating disorder has undergone several transformative shifts that are redefining care pathways and competitive dynamics. First, there is an increasing integration of digital therapeutics alongside traditional psychotherapy and pharmacotherapy, driven by improved mobile engagement models and a push for scalable behavioral interventions. Second, regulatory and reimbursement frameworks are slowly adapting to recognize the role of technology-enabled care, which in turn incentivizes investment in validated digital platforms and hybrid delivery models.
Third, precision in therapeutic targeting is improving as clinical research differentiates subgroups by comorbidity profiles and behavioral phenotypes, prompting more nuanced treatment algorithms that blend cognitive interventions with pharmacologic agents when indicated. Fourth, stakeholder collaboration is intensifying, with providers, payers, and technology developers exploring value-based agreements and outcome-based pilots to demonstrate cost-effectiveness and long-term benefit. Together, these shifts are creating an environment where multidisciplinary care, supported by interoperable data flows and outcome measurement, becomes the expectation rather than the exception, and where new entrants can compete by delivering demonstrable improvements in access, adherence, and measurable clinical outcomes.
An analytical review of how the cumulative effects of United States tariff adjustments in 2025 influenced supply chains, procurement choices, and cost strategies relevant to treatment delivery
In 2025, changes to tariff and trade policy in the United States influenced supply chains and procurement costs across several healthcare segments that intersect with binge eating disorder management. Supply chain sensitivity affected the availability and pricing of certain imported components used in digital devices and software-enabled services, while pharmaceuticals and medical devices experienced input-cost variability that cascaded into distribution and contracting negotiations. These pressures prompted some providers and specialty centers to reassess sourcing strategies, prioritize domestic procurement where feasible, and seek long-term supplier agreements to mitigate volatility.
Conversely, tariff-related cost shifts accelerated interest in localized manufacturing for hardware-dependent digital therapeutic platforms and created opportunities for domestic software vendors to gain pricing competitiveness relative to imports. For health systems and payers, the cumulative impact has emphasized the importance of robust procurement playbooks, scenario planning for input cost fluctuation, and contract clauses that share risk across stakeholders. As a result, organizations increasingly favor flexible contracting models and outcome-based arrangements that can absorb short-term cost variability while protecting long-term patient access to evidence-based treatment options.
Actionable segmentation insights that map therapeutic modalities, delivery channels, patient cohorts, and care settings to practical clinical and commercial levers
A nuanced view of market segmentation illuminates clinically meaningful pathways and operational priorities across treatment type, distribution channel, end user, and treatment setting. Based on treatment type, the landscape is studied across Digital Therapeutics, Pharmacotherapy, and Psychotherapy, with Digital Therapeutics further categorized into Mobile App and Web Based modalities, Pharmacotherapy further divided into Antidepressants, Antiepileptics, and Stimulants, and Psychotherapy further classified into Cognitive Behavioral Therapy, Dialectical Behavior Therapy, and Interpersonal Psychotherapy. Each of these subsegments carries distinct evidence requirements, implementation barriers, and value propositions, whether the emphasis is on scalable behavioral coaching, targeted symptom reduction, or integrated comorbidity management.
Based on distribution channel, the pathways considered include Home Healthcare, Hospitals And Clinics, Online Platforms, and Specialty Treatment Centers, each offering different access dynamics, clinician involvement levels, and reimbursement considerations. Based on end user, the analysis distinguishes Adolescents, Adults, and Elderly populations, recognizing divergent clinical presentations, engagement patterns, and caregiver involvement that affect both product design and care protocols. Based on treatment setting, the market is examined across Inpatient and Outpatient contexts, noting that inpatient pathways demand acute stabilization and multi-disciplinary coordination while outpatient models prioritize continuity, stepped care approaches, and digital augmentation. By mapping these multidimensional segments together, the analysis reveals where clinical need, payer interest, and commercial opportunity most strongly converge.
Key regional perspectives highlighting how clinical adoption, reimbursement complexity, and digital readiness drive differentiated strategies across global markets
Regional dynamics shape investment priorities, regulatory approaches, and adoption trajectories for binge eating disorder interventions. In the Americas, clinical awareness and payer innovation create a receptive environment for scalable digital solutions and outcome-driven pilots in integrated delivery systems. The United States, in particular, exhibits a growing appetite for hybrid care models that marry evidence-based psychotherapy with pharmacologic adjuncts, while Latin American markets demonstrate emerging interest in digital care to bridge provider shortages and urban-rural access gaps.
Across Europe, Middle East & Africa, regulatory heterogeneity and diverse reimbursement architectures mean that adoption is uneven but growing in markets with centralized health technology assessment pathways that can recognize long-term benefits. Stakeholders in these regions increasingly focus on cross-border clinical evidence generation and regionally tailored engagement strategies. In the Asia-Pacific region, rapid digital penetration, a strong appetite for mobile-first health solutions, and large adolescent and young adult populations present significant opportunities for mobile-based interventions and culturally adapted psychotherapeutic content. However, variations in stigma, health literacy, and service delivery capacity require nuanced localization strategies to realize adoption at scale. Taken together, regional strategies must balance standardized evidence packages with localized implementation planning to achieve sustainable uptake.
Insights into the strategic behaviors and collaborative models of pharmaceutical, digital therapeutics, and provider organizations shaping competitive dynamics
Leading organizations influencing the binge eating disorder ecosystem span pharmaceutical innovators, digital therapeutics developers, specialty treatment centers, and integrated provider networks. Pharmaceutical firms continue to pursue rigorous clinical development programs that explore pharmacologic mechanisms addressing compulsive eating behaviors and comorbid mood disorders, with an emphasis on safety, tolerability, and real-world effectiveness. Digital therapeutics companies focus on validated behavioral programs, engagement science, and interoperability, positioning their solutions as scalable complements or alternatives to traditional psychotherapy.
Specialty treatment centers and hospital systems act as critical early adopters and validation partners, running pragmatic pilots and providing longitudinal outcome data that inform payer decisions. Startups and academic collaborations drive innovation in measurement-based care and passive digital phenotyping, while established clinical research institutions contribute expertise in trial design and long-term follow-up. Across all these actors, strategic collaborations and licensing arrangements are increasingly common as companies seek to combine pharmacologic approaches with digital platforms or integrate evidence-based psychotherapies into reimbursable care pathways. Competitive advantage is conferred by demonstrable clinical outcomes, payer-aligned value propositions, and scalable implementation frameworks that lower the barrier for widespread adoption.
Practical and prioritized recommendations for leaders to validate clinical impact, secure payer alignment, and scale integrated care models for binge eating disorder
Industry leaders can take concrete actions to accelerate adoption, demonstrate value, and improve patient outcomes. First, invest in rigorous, pragmatic evidence generation that pairs clinical endpoints with real-world adherence and health-economic analyses to speak directly to payer concerns. Second, design integrated care pathways that combine validated psychotherapy protocols, appropriate pharmacologic options, and technology-enabled support to improve continuity and measurable outcomes across outpatient and inpatient settings. Third, prioritize interoperability and data standards to enable outcome tracking, seamless referral workflows, and the ability to participate in value-based contracting.
Fourth, tailor market access strategies by patient cohort, recognizing the distinct needs of adolescents, adults, and elderly groups, and by distribution channel, aligning product features with home healthcare, hospital, online platform, or specialty center workflows. Fifth, mitigate supply chain risk through diversified sourcing, flexible contracting, and contingency planning in response to trade and tariff pressures. Finally, pursue partnerships with payers and integrated delivery networks to pilot outcome-based reimbursement models that align incentives around sustained clinical improvement rather than episodic service delivery. These recommendations, implemented in concert, will position organizations to translate clinical innovation into durable, scalable care models.
A clear description of the mixed-methods research design, evidence sources, and validation steps used to generate actionable conclusions while acknowledging methodological limitations
The research underpinning this executive summary employs a mixed-methods approach that synthesizes peer-reviewed clinical literature, regulatory announcements, qualitative interviews with clinicians and payer executives, and a structured review of implementation case studies. Evidence selection prioritized randomized controlled trials, high-quality cohort studies, and pragmatic implementation reports that report clinically relevant endpoints and adherence metrics. Supplementary insights derive from expert interviews conducted with multidisciplinary clinicians, behavioral health directors, digital health product leaders, and policy advisors to capture practical barriers and enablers in real-world settings.
Data synthesis used thematic analysis to identify recurring implementation challenges and opportunities, supplemented by cross-validation against regulatory trends and reimbursement policy updates. Where applicable, gap analysis highlights areas needing further evidence, including long-term outcomes and comparative effectiveness across combined modality approaches. Limitations of the methodology include variability in outcome measurement across studies and heterogeneity in intervention designs, which the report addresses by standardizing endpoint definitions and transparently documenting inclusion criteria. This methodological rigor supports actionable conclusions while acknowledging areas where additional primary research would strengthen decision confidence.
A concise conclusion tying together clinical advances, delivery model evolution, and strategic priorities to guide stakeholders toward scalable, patient-centered care
This executive summary synthesizes the key dynamics shaping binge eating disorder care, highlighting the interplay between therapeutic innovation, delivery models, and system-level incentives. Clinically, the field is moving toward integrated approaches that pair psychotherapy with judicious pharmacologic support and technology-enabled adherence tools. Operationally, distribution choices and treatment settings influence implementation complexity and require tailored engagement strategies. Strategically, payer alignment and demonstrable value are central to mainstreaming new modalities and enabling sustainable patient access.
Looking forward, stakeholders who prioritize pragmatic evidence generation, invest in interoperable systems for outcome measurement, and pursue collaborative reimbursement pilots will be best positioned to scale effective interventions. The conclusions stress the importance of balancing near-term feasibility with long-term outcome monitoring, and of adopting patient-centered design to ensure interventions are acceptable, accessible, and equitable. Ultimately, the path to broader impact lies in coordinated efforts across clinical research, technology development, and payer engagement to transform promising innovations into standard care pathways that measurably improve lives.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
180 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Growing integration of telehealth platforms and virtual therapy for binge eating disorder patients
- 5.2. Increasing use of AI-powered personalized cognitive behavioral therapy applications for BED treatment
- 5.3. Emergence of novel pharmacological treatments targeting neurochemical pathways in binge eating disorder
- 5.4. Expansion of gut microbiome modulation strategies as adjunct therapy for binge eating disorder care
- 5.5. Rising investment in wearable technology and real-time monitoring for binge eating behavior tracking
- 5.6. Development of tailored nutritional guidance apps leveraging behavioral data for binge eating management
- 5.7. Shift toward value-based reimbursement models incentivizing outcomes in binge eating disorder treatment
- 5.8. Heightened focus on culturally sensitive interventions addressing binge eating in diverse populations
- 5.9. Advancements in digital peer support communities to reduce stigma around binge eating disorder
- 5.10. Integration of neuroimaging biomarkers and big data analytics to personalize binge eating interventions
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Binge Eating Disorder Market, by Treatment Type
- 8.1. Digital Therapeutics
- 8.1.1. Mobile App
- 8.1.2. Web Based
- 8.2. Pharmacotherapy
- 8.2.1. Antidepressants
- 8.2.2. Antiepileptics
- 8.2.3. Stimulants
- 8.3. Psychotherapy
- 8.3.1. Cognitive Behavioral Therapy
- 8.3.2. Dialectical Behavior Therapy
- 8.3.3. Interpersonal Psychotherapy
- 9. Binge Eating Disorder Market, by Treatment Setting
- 9.1. Inpatient
- 9.2. Outpatient
- 10. Binge Eating Disorder Market, by Distribution Channel
- 10.1. Home Healthcare
- 10.2. Hospitals And Clinics
- 10.3. Online Platforms
- 10.4. Specialty Treatment Centers
- 11. Binge Eating Disorder Market, by End User
- 11.1. Adolescents
- 11.2. Adults
- 11.3. Elderly
- 12. Binge Eating Disorder Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Binge Eating Disorder Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Binge Eating Disorder Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Alsana, Inc.
- 15.3.2. Amneal Pharmaceuticals, Inc.
- 15.3.3. Apotex Inc. by SK Capital Partners LLP
- 15.3.4. BALANCE Eating Disorder Treatment Center
- 15.3.5. Carolina House Eating Disorder Treatment Center
- 15.3.6. Center for Change
- 15.3.7. Equip Health, Inc.
- 15.3.8. Hikma Pharmaceuticals PLC
- 15.3.9. Jazz Pharmaceuticals plc
- 15.3.10. Johnson & Johnson Innovative Medicine by Johnson and Johnson
- 15.3.11. Monte Nido & Affiliates Holdings, LLC
- 15.3.12. Montecatini Eating Disorder Treatment Center
- 15.3.13. Novo Nordisk A/S
- 15.3.14. Pfizer Inc.
- 15.3.15. Red Oak Recovery
- 15.3.16. Rhodes Pharmaceuticals L.P. by Purdue Pharma L.P.
- 15.3.17. SimSon Pharma Limited
- 15.3.18. Sunovion Pharmaceuticals Inc. by Sumitomo Pharma
- 15.3.19. Takeda Pharmaceutical Company Limited
- 15.3.20. TalktoAngel
- 15.3.21. The London Centre for Eating Disorders and Body Image Ltd.
- 15.3.22. TheraCryf Plc
- 15.3.23. Timberline Knolls Residential Treatment Center
- 15.3.24. Viatris Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
